Efgartigimod – an anti-neonatal FC receptor (FcRn) antibody – is already approved by the FDA as an intravenous formulation called Vyvgart for gMG, becoming the first drug in the class to get a ...

Sanofi's decision to end development of the drug in myasthenia gravis may lie in the changing landscape of therapies for the disease, including the approval of Argenx' neonatal FC receptor (FcRn ...

And you can see that in recent examples like the Momenta acquisition where nipocalimab, we just got approved, our FcRn inhibitor ... many times one uses an IL-6 receptor inhibitor, namely toci ...

The firm believes both studies support its thesis that IMVT-1402 is a highly-derisked asset within the growing/strategically-important fragment crystallizable receptor space. Bottom line ...

The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia ...

"The newer medications that are coming out, and a lot of them are approved, are much more focused on the problem," explains ...